DEC 18, 2018 05:00 AM CST

Risk stratification of the apparently healthy population with ARCHITECT STAT High Sensitive Troponin-I

SPONSORED BY: Abbott Diagnostics
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Medical Director, Abbott Diagnostics
    Biography
      Dr. Murtagh is Associate Medical Director of Medical and Scientific Affairs for Abbott Diagnostics. Dr. Murtagh directs and implements clinical research activities, internal and external educational programs and business development projects in the cardiac space.

      Dr. Murtagh received her MD from Trinity College Dublin in 2003 before completing residency in Internal Medicine and specialty training in Cardiology (Advanced Cardiovascular Imaging and Cardio-Oncology at Northwestern Memorial and the University of Chicago). Dr. Murtagh has been involved in cardiovascular biomarker research for over ten years. She was co-chair of the ACC Working Group in Cardio-Oncology and has authored and co-authored multiple publications on biomarkers and imaging. She joined Abbott Diagnostics Division as Associate Medical Director in 2015.

    Abstract:
    DATE:    December 18, 2018
    TIME:    7:00am CST, 8:00am EST
     
    In this webinar you will hear about a recently CE marked application for ARCHITECT STAT High Sensitive Troponin I, that aids in providing greater accuracy for estimation of risk for future cardiac events in apparently healthy people, when used in conjunction with clinical and diagnostics findings. Risk is classified as low, moderate or elevated and use of ARCHITECT STAT High Sensitive Troponin I, is supported by a large body of evidence. This simple blood test can aid in earlier intervention for high risk patients and may avoid unnecessary tests and treatments in low risk patients.
    ARCHITECT STAT High Sensitive Troponin I, is well known to many through its use in Emergency Departments where it has been trusted for many years to rule in or rule out Myocardial Infarction. This latest application sets the stage to support tackling the cardiovascular disease burden through prevention.
     
    Learning objectives:
    • Understand the limitations of current risk assessment tools
    • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in predicting risk
    • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in earlier patient management for those at high risk
    • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in avoiding unnecessary tests and treatments in low risk patients
    • Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in reducing the growing cost burden of cardiovascular disease
    • Understand the body of evidence
     
     

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    Loading Comments...
    Show Resources